Global Tegoprazan Tablets Market Strategic Research Report

Scope of the Report

The global Tegoprazan Tablets market size is predicted to grow from US$ 137 million in 2025 to US$ 893 million in 2032; it is expected to grow at a CAGR of 17.3% from 2026 to 2032.

In 2025, global Tegoprazan Tablets production reached approximately 1 million units..Tegoprazan tablets are a novel, highly selective and reversible potassium‑competitive acid blocker (P‑CAB). By competitively inhibiting the potassium‑binding site of the H⁺/K⁺‑ATPase on gastric parietal cells, they exert rapid, potent and long‑lasting suppression of gastric acid secretion. Compared with conventional proton pump inhibitors, tegoprazan features a faster onset, more stable acid inhibition, no food effect, and a longer half‑life. Clinically, it is mainly indicated for the treatment of reflux esophagitis, gastric ulcer and duodenal ulcer, and can also be used for Helicobacter pylori eradication therapy. With favorable safety and tolerability, it has become an important first‑line drug for the treatment of acid‑related diseases.Tegoprazan: US$140 per units.

As the first domestic innovative P-CAB drug in China with full coverage of three core indications, tegoprazan tablets occupy an important position in the treatment of acid-related diseases owing to its clinical advantages of rapid and potent acid suppression, no food interaction, and high compliance. At present, there is huge domestic demand for acid-suppressive drugs, and P-CABs are rapidly replacing traditional PPIs. Relying on medical insurance coverage, complete indications and cost-effective advantages as a domestic drug, tegoprazan has established strong competitiveness in the middle and high-end markets.The market competition presents a tripartite pattern, featuring differentiated competition with imported vonoprazan and domestic caicloprazan, while facing potential pressure from accelerated generic drug applications. With the upgrading of clinical guidelines, full implementation of medical insurance policies and expanding demand for Helicobacter pylori eradication, tegoprazan has achieved simultaneous growth in hospital and retail channels, with broad long-term growth prospects.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Tegoprazan Tablets market?

What factors are driving Tegoprazan Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Tegoprazan Tablets market opportunities vary by end market size?

How does Tegoprazan Tablets break out by Type, by Application?

This report presents a comprehensive overview of the global Tegoprazan Tablets market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 7 tablets/box
• 14 tablets/box

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Production Technology

• Innovator
• Generic

Segment by Application

• Reflux Esophagitis
• Gastric Ulcer and Duodenal Ulcer
• Helicobacter pylori Eradication in Combination with Antimicrobial Agents
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Tegoprazan Tablets market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Reflux Esophagitis, Gastric Ulcer and Duodenal Ulcer, Helicobacter pylori Eradication in Combination with Antimicrobial Agents evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact